x

Search for a networks

* (*) mandatory field

A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)

  • Type of network : Multinational clinical trials
  • Geographic coverage : Global
  • Funding body(ies) : BAYER AG 
  • Sponsor : Information not provided
  • Coordinator of multinational clinical trial

  • INFORMATION NOT PROVIDED
  • Institution: Information not provided - DE
  • ADDRESS: NOT PROVIDED - DE
  • GERMANY
  • More information
  • Phone  : -
  • Fax  : -
Last update: June 2017

Additional information

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.